中国肺癌杂志2016，Vol.19Issue(5)：257-262,6.DOI:10.3779/j.issn.1009-3419.2016.05.02
107例KRAS突变阳性非小细胞肺癌患者临床分析
Clinical Analysis of 107 NSCLC Patients HarboringKRAS Mutation
张权 1吕嘉林 1张树才 1王敬慧 1李曦 1张卉 1农靖颖 1秦娜 1张新勇 1吴羽华 1杨新杰1
作者信息
- 1. 101149北京，首都医科大学附属北京胸科医院，北京市结核病胸部肿瘤研究所，肿瘤内科
- 折叠
摘要
Abstract
Background and objective Kirsten rat sarcoma viral oncogene (KARS) mutation is one of the major driver genes of non-small cell lung cancer (NSCLC). KARS is a resistant predictor of epidermal growth factor receptor tyrosine kinase inhibitors (EGFR-TKIs), which raises controversy because of its role in chemotherapy sensitivity and prognosis. hTe aim of this study is to accumulate clinical experience in treating NSCLC patients harboringKARSmutation.MethodsA total of 107 NSCLC patients harboringKARSmutation were analyzed retrospectively. hTe effcacy was analyzed in terms of ifrst-line chemotherapy or EGFR-TKIs therapy.Results hTe objective response rate (ORR) to ifrst-line chemotherapy of 52 pa-tients with advanced disease harboringKARS mutation was 9.6%. hTe disease control rate (DCR) was 53.8%, and the median progression-free survival (PFS) was 3 months. hTe ORR to EGFR-TKIs therapy in 21 patients harboringKARS mutation and EGFR/KARS co-mutation was 9.5%; the DCR was 23.8%, and the median PFS was 1 month. hTe ORR and DCR to EGFR-TKIs therapy of patients withEGFR/KARS co-mutation were signiifcantly higher than those of patients withKARS mutation (50%vs 0,P=0.029; 75%vs 11.8%,P=0.043); the median PFS was also signiifcantly longer (3 monthsvs 1 month,P=0.004). Conclusion hTe effcacy to ifrst-line chemotherapy and EGFR-TKIs therapy in NSCLC patients harboringKARS mutation was poor; thus, new drugs should be developed. Furthermore, the existence ofEGFR/KARS co-mutation was conifrmed. Hence, EGFR-TKIs therapy should be administered to patients withEGFR/KARS co-mutation.关键词
KARS突变/肺肿瘤/一线化疗/靶向治疗Key words
KARS mutation/Lung neoplasms/First-line chemotherapy/Targeted therapy引用本文复制引用
张权,吕嘉林,张树才,王敬慧,李曦,张卉,农靖颖,秦娜,张新勇,吴羽华,杨新杰..107例KRAS突变阳性非小细胞肺癌患者临床分析[J].中国肺癌杂志,2016,19(5):257-262,6.
